choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Viiv Healthcare

Viiv Healthcare Newsletter
  • Will miracle HIV drug go on the PBS? 04 Jul 2025 14:16 GMT

    … former president of the International AIDS Society. “But that’ … the Foundation for AIDS Research (amfAR), and HIV researchers and … be a difficult process. “ViiV Healthcare spent a long time … formerly the Australian Federation of AIDS Organisations), says it’s …

  • Analysis shows Yeztugo approval a ‘momentous step’ for HIV prevention 02 Jul 2025 17:17 GMT

    … adolescents at risk of HIV exposure. GlobalData infectious … alafenamide), as well as ViiV Healthcare’s Apretude (cabotegravir). … HIV through PrEP and maximising Yeztugo sales.” The Elton John AIDS … effective prevention technology for HIV transmission”. In a …

  • Gilead Eyes HIV Market Domination With Twice-Yearly Yeztugo as GSK Trails 02 Jul 2025 04:07 GMT

    … Yeztugo could serve targeted populations. GSK Gears Up for Market Share … U.K. pharma’s HIV joint venture ViiV Healthcare, Apretude sales rose around … sales to contract. GSK sees things differently. ViiV Chairman David Redfern said …

  • Cost, insurance limits threaten global progress in HIV treatment 02 Jul 2025 03:40 GMT

    … patients. Access to newer HIV therapies remains a major … challenge in the global HIV treatment landscape, largely due … and prevention therapies such as ViiV Healthcare’s Apretude (cabotegravir) … report, Human Immunodeficiency Virus (HIV): Seven-Market (7M) Drug …

  • Twice Yearly HIV Prevention Shot, Yeztugo, May Face Access Hurdles 01 Jul 2025 16:37 GMT

    … quest to end the HIV/AIDS epidemic that still costs … a year. By comparison, ViiV charges around $24,000 annually … working closely with insurers, healthcare systems, and pharmacy benefit … has slashed federal support for HIV treatment, prevention, and …

  • HIV prevention: Daily oral versus long-acting injectables 01 Jul 2025 07:50 GMT

    … concluded 10th Asia Pacific AIDS and Co-Infections Conference … in protecting us from HIV. It involves injections … tenofovir and emtricitabine) for HIV prevention among cisgender women … July 2022, its manufacturer ViiV Healthcare announced a voluntary license …

  • Integrase Inhibitors Market Set to Witness Significant Growth by 2025-2032 | Gilead Sciences, ViiV Healthcare group 26 Jun 2025 13:56 GMT

    … and increasing government healthcare funding targeting HIV treatment expansion. - … insights is optimizing personalized HIV therapies addressing resistance variations, … Competitive strategies include: - ViiV Healthcare’s focus on strategic collaborations …

  • GSK (GSK) Gains FDA Approval for Benlysta Autoinjector for Lupus Treatment 28 Jun 2025 16:50 GMT

    … five years and above. GSK (GSK) Gains FDA Approval … their caregivers immediately. GSK plc (NYSE:GSK) is a … (asthma), and HIV treatments through its ViiV Healthcare joint venture. While … we acknowledge the potential of GSK

  • By maintaining Obamacare pillar, Supreme Court hands win to HIV advocates 27 Jun 2025 19:29 GMT

    … modest decline recently in HIV cases, and HIV advocates stand at … and uncertainty about Kennedy HIV advocates expressed concern that … the medical approach to HIV/AIDS in the past, and … as PrEP. In late 2021, ViiV Healthcare’s Apretude — an injection …

  • Sally Gunnell relishing taking part in latest Tackle HIV challenge 27 Jun 2025 03:42 GMT

    … in the past around AIDS and HIV, so events like … proved invaluable, according to Viiv Healthcare’s Helen McDowell. “We … HIV is a campaign led by Gareth Thomas in partnership with ViiV Healthcare … stigma and misunderstanding around HIV. For more information visit …

Satisfied with the content?

Continue to create your account.